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Over 25 clinical trials for sepsis have failed [1,2], suggest-
ing that our current understanding of its pathogenesis is
incomplete. Deaths occur days to weeks after diagnosis
and have been attributed to one of two phenomena [3].
First, a subset of patients succumbs to an overwhelming
acute inflammatory response driven by the innate immune
system, leading to death within days of the initial infec-
tion. However, most patients survive this phase and the
repeated failure of anti-inflammatory therapies for sepsis
(for example, anti-tumor necrosis factor antibodies [4],
high-dose corticosteroids [5]) indicates that inflammation
per se is unlikely to be a major cause of death. Most sepsis
deaths occur later and have been associated with dys-
function of the innate and adaptive immune systems
[6], characterized by decreased cytokine production
and lymphocyte apoptosis [7]. These mechanisms have
been postulated to cause immunosuppression [3,8,9],
predisposing patients to fatal nosocomial infections.
Based on this hypothesis, immunoadjuvant therapy to
boost the immune system has been proposed recently
as a therapeutic approach.
The argument against nosocomial infection
The notion of death due to nosocomial infection is at
odds with our clinical experience, in which patients with
sepsis die despite broad-spectrum antibiotics and negative
microbial cultures. Indeed, two studies often cited as
evidence for this theory are open to alternative interpre-
tations. The first study reported a high (~80 %) rate of
infected foci in those patients dying from sepsis [10].
Yet it was unclear whether culture data reflected only
postmortem or perimortem cultures, or incorporated
laboratory results taken earlier during hospitalization –
a period in which positive cultures would be expected.* Correspondence: leew@smh.ca
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article, unless otherwise stated.The second study did not report the incidence of positive
cultures in patients who died from sepsis, a critical
statistic for determining the contribution of nosocomial
infection to mortality [1]. This study described three
phases of mortality, divided into deaths occurring within
hospital days 0 to 5 (phase I), days 6 to 15 (phase II) and
days 16 to 150 (phase III). Despite the fact that phase III
included the largest number of days by far, the mortality
rate was highest in phase I, arguing against late nosoco-
mial infection being the main cause of death.
A recent retrospective analysis in our own center has
provided further evidence against this theory. We consid-
ered all patients admitted to the ICU who were screened
for a sepsis study of heparin (Heparin Anticoagulation to
Improve Outcomes in Septic Shock; ClinicalTrials.gov
NCT 1648036) and subsequently died. From these
patients, we selected those who actually had sepsis and
looked for evidence of a secondary nosocomial infec-
tion, defined as a detected new microbial isolate prior
to death. Of 26 consecutive patients dying of septic
shock in a mixed medical–surgical ICU, only three
(14 %) patients had evidence of a new infection at the
time of death (Table 1). While our study is not defini-
tive, taken together with other results, the theory that
nosocomial infection is the predominant cause of death
from sepsis seems tenuous.If not infection, what else?
Mitochondrial dysfunction
There is substantial evidence for mitochondrial dysfunction
in sepsis [11]. The theory is that if perfusion and oxygen
content are adequate but organ dysfunction still exists,
the cells must be unable to use oxygen. Several factors,
including reactive oxygen species, hormonal deficiencies,
and the impact of systemic inflammation on mitochon-
drial gene transcription, are thought to contribute [11,12].
Furthermore, leukocytes from septic patients have been
shown to possess abnormal oxygen metabolism [13], and
mitochondrial dysfunction has been associated with poor
outcomes in septic shock [14]. While trials of antioxidantntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Lack of evidence of nosocomial infection in a retrospective cohort of patients dying of sepsis










70 to 79 Lung 12 16 13 1 No growth Cancer No nosocomial infection
60 to 69 Skin and soft tissue 9 55 55 5 No growth CHF No nosocomial infection
80 to 89 Genitourinary 12 1 14 2 No growth CHF No nosocomial infection
70 to 79 Bloodstream 15 17 17 2 Original organism IE/sepsis No nosocomial infection
80 to 89 Lung 18 54 73 <1 Original organism Ischemic bowel No nosocomial infection
40 to 49 Intra-abdominal 12 14 14 14 No growth Liver failure No nosocomial infection
80 to 89 Lung 11 12 10 1 No growth MI No nosocomial infection
70 to 79 Lung 10 5 3 1 Original organism MI No nosocomial infection
40 to 49 Bloodstream 21 14 4 1 No growth MOF No nosocomial infection
50 to 59 Bloodstream 15 16 33 3 No growth MOF No nosocomial infection
40 to 49 Intra-abdominal 17 4 5 1 No growth MOF No nosocomial infection
70 to 79 Intra-abdominal 16 42 43 3 No growth MOF No nosocomial infection
60 to 69 Lung 9 19 18 2 No growth MOF No nosocomial infection
50 to 59 Skin and soft tissue 13 10 11 1 No growth MOF No nosocomial infection
60 to 69 Skin and soft tissue 14 76 57 2 No growth MOF No nosocomial infection
<30 Skin and soft tissue 14 86 85 <1 No growth MOF No nosocomial infection
80 to 89 Genitourinary 16 1 1 1 Original organism MOF No nosocomial infection
70 to 79 Lung 4 34 22 3 No growth Tumor lysis No nosocomial infection
40 to 49 Intra-abdominal 7 46 74 1 New organism MOF Nosocomial infection
70 to 79 Intra-abdominal 5 6 6 1 New organism MOF Nosocomial infection
<30 Intra-abdominal 12 37 37 <1 New organism Pancreatitis Nosocomial infection
60 to 69 Intra-abdominal 5 1 7 3 New organism MOF Indeterminate
50 to 59 Skin and soft tissue 12 37 37 4 No growth MOF Indeterminate
40 to 49 Lung 16 68 50 6 No growth MOF Indeterminate
70 to 79 Lung 13 17 17 13 Original organism MOF Indeterminate
70 to 79 Intra-abdominal 14 3 13 <1 No growth Sepsis Indeterminate
The initial antibiotic therapy was checked against culture and sensitivity results to record the appropriateness of antibiotic therapy for the initial isolate. Results of the final culture before death and the time from that
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trials are needed to determine the validity of this approach.
Microvascular leak
Another theory for death from sepsis implicates systemic
vascular leak (Figure 1) [15,16]. Loss of endothelial barrier
integrity leads to tissue edema, hypoperfusion, and organ
dysfunction. These features are characteristic of human
sepsis but until recently were absent from animal models.
Importantly, various lines of evidence for this theory exist.
In mice, buttressing the endothelial barrier directly
protected against death from sepsis [17,18]. In humans,
limiting fluids accelerated recovery in acute respiratoryFigure 1 Evidence supporting nosocomial infection as the major caus
of mitochondrial dysfunction as well as systemic microvascular leak (see tedistress syndrome [19], while a positive fluid balance
was associated with worse outcome in sepsis [20]; most
recently, in a post hoc subgroup of the sickest sepsis
patients, albumin therapy – which would limit edema
formation – was also protective [21].
Conclusion
Sepsis has been termed a pharmaceutical ‘graveyard’ [22]
due to repeated failure of human clinical trials. Despite
calls for a trial of immunoadjuvant therapy, the evidence
supporting nosocomial infection as the main cause of
death is weak. A small study of granulocyte–macrophage
colony-stimulating factor in patients with severe sepsis/e of death in sepsis is weak. Alternative hypotheses include the role
xt). ARDS, acute respiratory distress syndrome.
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but no significant change in a host of clinical parameters
except for the duration of mechanical ventilation [23].
Practically, if most patients who die from sepsis have
sterile cultures, it is unlikely that boosting the immune
system or adding additional antibiotics will improve
outcomes. Further research into the contribution of
nosocomial infection to sepsis mortality is thus necessary,
as well as research into other potential contributors such
as systemic microvascular leak.
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